.
Looking at the side effects though, its something like knowing salvation is on the next island over but to get there you would have to swim a couple of miles across a channel foaming due to the thrashing of hundreds of hungry great whites.
Probably best to lengthen your time left after a severely poor
prognosis.
Definitely one of those breakthroughs to a new vision on healthcare sort of moments, those first couple steps toward that future though are going to be a doozy.
CM; Thanks! In one of the linked and related articles they suggest that short exposure to rapamycin early in life may have an effect that lasts in to old age. This is, of course, all research based on mice and fruit flies so it would be wrong to draw any firm conclusions for humans.
https://medicalxpress.com/news/2023-04-perspective-cancer-rapamycin.html
The scientists have tested different time windows of short-term drug administration in fruit flies and found that a brief window of two weeks of rapamycin treatment in young, adult flies protected them against age-related pathology in the intestine and extended their lives. A corresponding short time window, three months of treatment starting at three months of age in young, adult mice, had similar beneficial effects on the health of the intestine when they were middle-aged.
“These brief drug treatments in early adulthood produced just as strong protection as continuous treatment started at the same time. We also found that the rapamycin treatment had the strongest and best effects when given in early life as compared to middle age. When the flies were treated with rapamycin in late life, on the other hand, it had no effects at all. So, the rapamycin memory is activated primarily in early adulthood,” explains Dr. Thomas Leech, co-author of the paper.
https://www.eurekalert.org/news-releases/897033 Snip...
"Their analysis identified many novel candidate metformin and rapamycin mimetics that have been previously unreported as such. In particular, they identified allantoin and ginsenoside as strong mimetics of metformin, epigallocatechin gallate and isoliquiritigenin as strong mimetics of rapamycin, and withaferin A as a strong mimetic of both. Additionally, their analysis also identified four previously unexplored natural compounds as fairly strong mimetic of rapamycin.
"Aging is not recognized as a disease, so we need strong potential geroprotectors of natural origin on the market. Supplements that slow down aging, affecting the key mechanisms of aging at the molecular and cellular level" said Alexey Moskalev, PhD, a co-author of the study.
These findings are significant because, as naturally occurring compounds, such nutraceuticals are not subject to regulation by the FDA and other regulatory bodies. Furthermore, because the researchers induced a deep-learning based classification of the safety profiles associated with these compounds, the novel candidate mimetics the study identified are likely to have less adverse effects than metformin and rapamycin, though this needs to be further validated by clinical testing."